RxDoctor Payments Data

Ajay Thakur, MD

Interventional Cardiology · Celebration, FLNPI 1770571846

Payments from drug & device makers

$1,423in general payments, 2019–2025

Across 39 payments — averaging $36.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$268
  • Astellas Pharma US Inc$196
  • Abbott$145
  • Vital Connect, Inc$129
  • Kestra Medical Technology Services, Inc.$96
  • Abiomed$95
  • plus $495 from 17 others

What the payments were for

  • Food & beverage$1,24888%
  • Education$17512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,423 in reported general payments places this provider in the 10th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$202,320
Medicare patients
481
Services billed
2,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban255$268,325
JardianceEmpagliflozin123$107,006
EntrestoSacubitril/Valsartan71$75,632
Repatha SureclickEvolocumab40$41,363
XareltoRivaroxaban34$38,721
MultaqDronedarone Hcl25$33,077
VascepaIcosapent Ethyl12$10,464
Rosuvastatin Calcium223$3,072
Metoprolol Succinate178$2,953
Ranolazine ErRanolazine31$2,578
Ezetimibe117$1,836
Atorvastatin Calcium158$1,447
Losartan Potassium188$1,294
Nebivolol Hcl11$1,254
Amlodipine Besylate164$1,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$268,325255 claims
Boehringer IngelheimJardiance$30$107,006123 claims
NovartisEntresto$37$75,63271 claims
Johnson & JohnsonXarelto$20$38,72134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Celebration

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →